Influence of betahistine repeated administration on a weight gain and selected metabolic parameters in the model of excessive eating in rats.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 09 04 2021
revised: 24 06 2021
accepted: 28 06 2021
pubmed: 7 7 2021
medline: 16 12 2021
entrez: 6 7 2021
Statut: ppublish

Résumé

It is important to search for a promising therapeutic target or small molecules that can control excessive eating since limiting the intake of foods, especially tasty ones, could be effective in the treatment or prevention of obesity. Some studies indicate betahistine as an unique drug having the ability to ameliorate, for example, antipsychotic-induced weight gain. This study aimed to determine whether repeated administration of betahistine (histamine H1R agonist and H3R antagonist) could be beneficial in reducing the intake of tasty foods or the body's response to overeating via mechanisms such as by influencing the levels of hormones involved in the regulation of food intake or the levels of selected metabolic parameters. Studies were performed in the excessive eating model in rats, which perfectly illustrates the harmful high-caloric intake from freely available tasty products rich in sugar and fat. Our results indicated that repeated administration of betahistine to rats caused lower gain of body mass compared to the control rats fed palatable feed. Interestingly, betahistine treatment increased the consumption of cheese, which is a source of histamine. Although betahistine did not prevent the development of metabolic disorders, such as reduced glucose tolerance, in test animals, it significantly increased the level of high-density lipoprotein cholesterol, which could certainly be considered beneficial. Further studies should be conducted to investigate the effect of repeated administration of betahistine on satiety, gastrointestinal disorders, and the preference for histamine-containing foods.

Identifiants

pubmed: 34229247
pii: S0753-3322(21)00674-0
doi: 10.1016/j.biopha.2021.111892
pii:
doi:

Substances chimiques

Anti-Obesity Agents 0
Dietary Fats 0
Histamine Agonists 0
Hormones 0
Sugars 0
Betahistine X32KK4201D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111892

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Kamil Mika (K)

Department of Pharmacological Screening, Jagiellonian University Medical College, Medyczna 9, PL 30-688 Cracow, Poland.

Małgorzata Szafarz (M)

Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.

Jacek Sapa (J)

Department of Pharmacological Screening, Jagiellonian University Medical College, Medyczna 9, PL 30-688 Cracow, Poland.

Magdalena Kotańska (M)

Department of Pharmacological Screening, Jagiellonian University Medical College, Medyczna 9, PL 30-688 Cracow, Poland. Electronic address: magda.dudek@uj.edu.pl.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH